Gilead Sciences expanded its cell therapy portfolio by acquiring Interius BioTherapeutics for $350 million, gaining in vivo CAR-T technology that enables direct genetic modification of immune cells within the patient. This strategic acquisition marks a shift from traditional ex vivo CAR-T approaches, aiming to simplify therapy administration and broaden patient access. The deal highlights intensifying competition in next-generation cell therapies focused on safety, scalability, and efficacy.